Core Viewpoint - The case of ST Lifan highlights the severe consequences of systematic financial fraud in the A-share market, leading to administrative penalties and potential delisting due to significant violations of financial reporting standards [3][4]. Group 1: Company Overview - ST Lifan (300344.SZ) is facing administrative penalties and a potential delisting process due to long-term systematic financial fraud, as announced by the China Securities Regulatory Commission (CSRC) [3]. - The company has been found to have inflated revenues and costs by a total of 638 million yuan from 2021 to 2023, with specific annual figures indicating 280 million yuan in 2021, 312 million yuan in 2022, and 46 million yuan in 2023 [4][5]. Group 2: Regulatory Actions - The CSRC has proposed a fine of 10 million yuan against ST Lifan and a total of 30 million yuan in fines against ten responsible individuals, including a 10-year market ban for three senior executives [3][6]. - The company’s financial reports for 2021, 2022, and 2023 have been identified as containing false records, with the false revenue for 2021 and 2022 alone accounting for over 50% of the reported annual revenue [4][6]. Group 3: Fraud Mechanisms - ST Lifan employed various fraudulent methods, including agency business, financing trade, and fictitious trade, to inflate both revenue and costs [5]. - Key individuals, including the chairman and other executives, have been implicated for neglecting their duties and allowing fraudulent activities to occur [5][6]. Group 4: Market Impact - Following the announcement of the delisting risk, ST Lifan's stock price fell by 5.62% to 3.36 yuan on the day of the major delisting risk disclosure [4]. - The company is also facing additional legal challenges, including a contract dispute involving over 61 million yuan, which is linked to an ongoing criminal investigation [6]. Group 5: Investor Protection and Governance - The case underscores the need for stronger internal controls and independent oversight within companies to prevent financial misconduct [8]. - Recent legal cases in China have shown a shift towards collective investor protection mechanisms, indicating a growing trend in safeguarding investor rights against corporate fraud [7][8].

立方数科股份有限公司（下称"立方数科"，300344）严重财务造假案件被严肃查处。 11月28日，证监会表示，近日，证监会对上市公司立方数科涉嫌定期报告财务数据存在虚假记载作出行 政处罚及市场禁入事先告知。 "经查，2021年至2023年，立方数科通过开展代理业务、融资性贸易、虚假贸易等方式，累计虚增收入 6.38亿元、成本6.28亿元。其中，2021年收入、成本分别虚增2.80亿元、2.77亿元，2022年收入、成本分 别虚增3.12亿元、3.05亿元，2023年收入、成本分别虚增0.46亿元、0.45亿元。"证监会表示。 立方数科连续三年虚增收入和成本，严重违反证券法律法规，安徽证监局拟对立方数科处以1000万元罚 款，对汪逸等10名责任人合计罚款3000万元。同时，立方数科涉嫌触及重大违法强制退市情形，深交所 将依法启动退市程序。 此外，证监会进一步指出，决定对本案所涉会计师事务所执业行为正式立案调查，涉嫌未能勤勉尽责的 将依法严惩。对于相关违法行为可能涉及的证券犯罪问题线索，将坚持应移尽移的工作原则，依法依规 移送公安机关。 智通财经记者查阅立方数科2021年、2022年、2023年的年报显示，立方数 ...

END 点击关键字可查看 潜望系列深度报道丨 股事会专栏 丨 投资小红书 丨 e公司调查 丨 时报会客厅 丨 十大明星私募访谈 丨 芯片巨头，大涨！ 丨 603388，退市！ 丨 A股，重要调整！ 丨 突然异动！这一板块，大爆发！ 丨 证监会剑指财务造假，发行人+中介机构被同步追责 丨 摩尔线程，最新发布！ 丨 002702，地天 板！ 丨 俄乌，最新消息！普京表态 丨 10倍牛股，停牌核查！ 丨 近9000亿元！上交所最新发声 丨 午后，直线拉升！ 丨 丨 爆发！这一板块，涨停潮！ 丨 万科，股债双杀！ 丨 美联储，重磅发布！美 股全线上涨 解码港股IPO版图：四地企业占据半壁江山、三四线城市靠巨头榜上有名… 新华社快讯：29日上午，香港特区行政长官李家超、特区政府主要官员和公务员等在政府总部举行悼念活动， 哀悼大埔宏福苑火灾中不幸罹难的人士。特区政府建筑物国旗和区旗下半旗。 来源：新华社 责编：万健祎 校对：王朝全 版权声明 证券时报各平台所有原创内容，未经书面授权，任何单位及个人不得转载。我社保留追 究相关 行 为主体 法律责任的权利。 转载与合作可联系证券时报小助理，微信ID：SecuritiesTi ...

Core Viewpoint - R Puli 1 (Puli Pharmaceutical Co., Ltd.) is facing significant regulatory scrutiny and financial challenges, including a recent fine for failing to disclose its 2024 annual report on time, which adds to its existing issues related to previous financial misconduct [1][2][3]. Group 1: Regulatory Issues - On November 28, R Puli 1 received an administrative penalty notice from the Hainan Regulatory Bureau of the China Securities Regulatory Commission (CSRC) for not disclosing its 2024 annual report within the legal timeframe, resulting in a fine of 500,000 yuan [1]. - The company had previously faced penalties for financial fraud, including a total of 1.029 billion yuan in inflated revenue and 669 million yuan in inflated profits over two years, leading to a fine of 10 million yuan and market bans for key executives [3]. Group 2: Financial Challenges - As of the end of Q3 2024, R Puli 1 reported cash reserves of only 331 million yuan, while its short-term liabilities due within a year amount to 541 million yuan, indicating a concerning short-term solvency issue [4]. - The company is under significant pressure from both the risk of delisting and a looming debt crisis, exacerbated by the recent regulatory penalties [4].

● 本报记者昝秀丽 证监会11月28日消息，近日，证监会对立方数科涉嫌定期报告财务数据存在虚假记载作出行政处罚及市 场禁入事先告知。 经查，2021年至2023年，立方数科通过开展代理业务、融资性贸易、虚假贸易等方式，累计虚增收入 6.38亿元、成本6.28亿元。立方数科连续三年虚增收入和成本，严重违反证券法律法规，安徽证监局拟 对立方数科处以1000万元罚款，对汪逸等10名责任人合计罚款3000万元。立方数科涉嫌触及重大违法强 制退市情形，深交所将依法启动退市程序。 同时，证监会决定对本案所涉会计师事务所执业行为正式立案调查，涉嫌未能勤勉尽责的将依法严惩。 对于相关违法行为可能涉及的证券犯罪问题线索，证监会将坚持应移尽移的工作原则，依法依规移送公 安机关。 此案是首例上市公司领罚单，中介机构被同步立案的典型，体现了监管部门打击财务造假"追首 恶"与"打帮凶"并重的导向，标志着全方位、立体式的综合惩防体系进一步走向深入。 据悉，立方数科或是今年第14家因财务造假而涉嫌触及重大违法强制退市的公司，年内触及重大违法强 制退市的公司数量创历年新高。这一变化源于退市新规对财务造假退市标准的调整，也源于严监严管 下，监 ...

同时，证监会决定对本案所涉会计师事务所执业行为正式立案调查，涉嫌未能勤勉尽责的将依法严惩。 对于相关违法行为可能涉及的证券犯罪问题线索，证监会将坚持应移尽移的工作原则，依法依规移送公 安机关。 ● 本报记者 昝秀丽 此案是首例上市公司领罚单，中介机构被同步立案的典型，体现了监管部门打击财务造假"追首 恶"与"打帮凶"并重的导向，标志着全方位、立体式的综合惩防体系进一步走向深入。 证监会11月28日消息，近日，证监会对立方数科涉嫌定期报告财务数据存在虚假记载作出行政处罚及市 场禁入事先告知。 据悉，立方数科或是今年第14家因财务造假而涉嫌触及重大违法强制退市的公司，年内触及重大违法强 制退市的公司数量创历年新高。这一变化源于退市新规对财务造假退市标准的调整，也源于严监严管 下，监管部门对财务造假"零容忍"的立场，以及打破造假"生态圈"的决心。 经查，2021年至2023年，立方数科通过开展代理业务、融资性贸易、虚假贸易等方式，累计虚增收入 6.38亿元、成本6.28亿元。立方数科连续三年虚增收入和成本，严重违反证券法律法规，安徽证监局拟 对立方数科处以1000万元罚款，对汪逸等10名责任人合计罚款3000万元。 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued a notice of administrative penalty against Lifan Shuke Co., Ltd. for financial fraud, which includes a total fine of 40 million yuan and the initiation of delisting procedures due to serious violations of securities laws [1][2]. Group 1: Financial Fraud Details - Lifan Shuke has inflated its revenue by 638 million yuan and costs by 628 million yuan from 2021 to 2023 through various fraudulent activities [2]. - The breakdown of inflated figures includes 280 million yuan in revenue and 277 million yuan in costs for 2021, 312 million yuan in revenue and 305 million yuan in costs for 2022, and 46 million yuan in revenue and 45 million yuan in costs for 2023 [2]. Group 2: Regulatory Actions - The CSRC has intensified its crackdown on financial fraud, with 14 companies facing potential delisting due to serious violations, marking a historical high [3]. - The CSRC has also decided to investigate the accounting firm involved in Lifan Shuke's case, marking a significant step in holding intermediary institutions accountable [4]. Group 3: Impact on Intermediary Institutions - Over 40 accounting firms have been penalized for negligence in financial fraud cases, with total fines exceeding 300 million yuan this year [4]. - The regulatory body has increased penalties against intermediary institutions to enhance accountability and deter collusion in fraudulent activities [5].

Core Viewpoint - R Puli 1 (Puli Pharmaceutical Co., Ltd.) is facing significant regulatory scrutiny and financial challenges, including a recent fine for failing to disclose its 2024 annual report on time, amidst ongoing concerns about its previous financial misconduct and potential delisting [1][2][3][4]. Regulatory Issues - On November 28, R Puli 1 received an administrative penalty notice from the Hainan Regulatory Bureau of the China Securities Regulatory Commission for not disclosing its 2024 annual report within the legal timeframe, resulting in a fine of 500,000 yuan and a warning [1]. - This is not the first regulatory issue for R Puli 1; the company was previously penalized for financial fraud, which included inflating revenue by 1.029 billion yuan and profits by 669 million yuan over two years [3]. Financial Challenges - As of the end of Q3 2024, R Puli 1 reported cash reserves of only 331 million yuan, while its short-term liabilities due within a year amount to 541 million yuan, indicating a concerning short-term solvency situation [4]. - The company is under significant pressure due to the combination of delisting risks and a looming debt crisis, raising fears of potential defaults [4]. Company Background - R Puli 1 was established in 1992 and listed on the Growth Enterprise Market in 2017, previously recognized as one of China's top 100 innovative listed companies, with a diverse product line in various therapeutic areas [4].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued administrative penalties against Shenyang Chemical Co., Ltd. and several individuals for violations related to false financial disclosures from 2018 to 2021 [2][4][5]. Group 1: Violations and Findings - Shenyang Chemical's subsidiary, Shenyang Wax Chemical, manipulated financial data by adjusting production input quantities and delaying inventory recognition, leading to false reporting in annual reports [4][5]. - Specific financial discrepancies include: - 2018: Reduced operating costs by CNY 129.91 million, inflated profit by 80.44% [4]. - 2019: Reduced operating costs by CNY 204.50 million, inflated profit by 29.4% [4]. - 2020: Reduced operating costs by CNY 104.23 million, inflated profit by 19.14% [4]. - 2021: Inflated operating costs by CNY 147.76 million, reduced profit by 70.11% [4]. Group 2: Penalties Imposed - Shenyang Chemical was fined CNY 7 million and received a warning [9]. - Key individuals received the following penalties: - Sun Zesheng (Chairman and General Manager): fined CNY 3.5 million and banned from the securities market for 8 years [7][9]. - Li Zhong (Chief Accountant): fined CNY 3 million and banned for 4 years [8][9]. - Yang Lin (Director): fined CNY 1.2 million [9]. - Leng Zhaojia (Finance Head): fined CNY 1 million [9].

11月28日，证监会披露，安徽证监局拟对连续三年财务造假的立方数科（ST立方，300344.SZ）处以 1000万元罚款，对10名责任人合计罚款3000万元。立方数科涉嫌触及重大违法强制退市情形，深交所将 依法启动退市程序。 证监会同时指出，该会决定对本案所涉会计师事务所执业行为正式立案调查，涉嫌未能勤勉尽责的将依 法严惩。对于相关违法行为可能涉及的证券犯罪问题线索，该会将坚持应移尽移的工作原则，依法依规 移送公安机关。 《中国经营报》记者查询发现，中兴财光华会计师事务所（以下简称"中兴财光华"）对立方数科2021年 至2023年年报连续三年出具了标准无保留意见审计报告。 受访律师表示，通过行政处罚、市场禁入、刑事追责的环环相扣，监管部门构建起全方位、全链条的追 责体系，彰显对财务造假"零容忍"的法律态度。 连续三年财务造假 安徽证监局在11月28日下发的《行政处罚及市场禁入事先告知书》中指出，立方数科通过开展代理业 务、融资性贸易、虚假贸易虚增营业收入、营业成本、利润总额，导致立方数科披露的2021年至2023年 年度报告存在虚假记载。 经查，2021年至2023年，立方数科累计虚增收入6.38亿元、成本6 ...